Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities from Discontinued Operations (2018 - 2023)

Historic Liabilities from Discontinued Operations for Aclaris Therapeutics (ACRS) over the last 6 years, with Q4 2023 value amounting to $2.2 million.

  • Aclaris Therapeutics' Liabilities from Discontinued Operations changed 0.0% to $2.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.2 million for FY2023, which is 0.0% changed from last year.
  • Latest data reveals that Aclaris Therapeutics reported Liabilities from Discontinued Operations of $2.2 million as of Q4 2023, which was down 0.0% from $2.2 million recorded in Q3 2023.
  • Aclaris Therapeutics' Liabilities from Discontinued Operations' 5-year high stood at $14.5 million during Q3 2019, with a 5-year trough of $2.2 million in Q3 2021.
  • For the 5-year period, Aclaris Therapeutics' Liabilities from Discontinued Operations averaged around $3.2 million, with its median value being $2.2 million (2021).
  • In the last 5 years, Aclaris Therapeutics' Liabilities from Discontinued Operations tumbled by 7724.29% in 2020 and then surged by 3516.82% in 2021.
  • Over the past 5 years, Aclaris Therapeutics' Liabilities from Discontinued Operations (Quarter) stood at $4.2 million in 2019, then fell by 25.16% to $3.1 million in 2020, then dropped by 29.22% to $2.2 million in 2021, then changed by 0.0% to $2.2 million in 2022, then changed by 0.0% to $2.2 million in 2023.
  • Its last three reported values are $2.2 million in Q4 2023, $2.2 million for Q3 2023, and $2.2 million during Q2 2023.